The Oncotype DX Breast Recurrence Score test is a diagnostic test performed after a breast cancer surgery or biopsy, and provides information that’s important for treatment planning—such as an assessment of risk of distant recurrence1,3 and whether chemotherapy will be beneficial for your patient.2, 4
Patients are eligible for the Breast Recurrence Score test if they are:
- Recently diagnosed with invasive breast cancer
- Medically eligible for chemotherapy
And the cancer is:
- Anatomic stage I, II, or IIIa
- Estrogen-receptor positive (ER+)
- Human epidermal growth factor receptor-negative (HER2-)
NOTE: If your patient has been diagnosed with non-invasive breast cancer, ductal carcinoma in situ (DCIS) she may be eligible for the Oncotype DX Breast DCIS Score test.
The Breast Recurrence Score test can provide insight into specific diagnoses, treatment options, or risks factors, such as:
When to order the test
Because the goal of the Breast Recurrence Score test is to facilitate treatment planning, the best time to order the test is before treatment planning begins. Ordering is easy, and the test can be run on a post-surgery (lumpectomy or mastectomy) tumour sample or on a core biopsy.
The Oncotype DX test has been available in Canada since the end of 2007, and to date, over 30,000 Canadian women have benefited from testing. There is publicly funded coverage for the Oncotype DX Recurrence Score Assay patients in a number of Canadian provinces including British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, PEI and Newfoundland. Individual patients also have the option of paying for the test themselves if there is no coverage in their province, or if they do not meet pre-specified provincial eligibility criteria. For further information, please contact Genomic Health Customer Service.